PCRX
Pacira BioSciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$26.35
−0.94%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
8.6x
EV/EBITDA
10.6x
Market Cap
$1.05B
MomentumView details →
1D Return
−0.94%
YTD Return
+2.38%
RSI (14)
61.2
ValuationView details →
P/E (Fwd)
8.6x
EV/EBITDA
10.6x
Market Cap
$1.05B
RSI (14)
61.2
MomentumView details →
1D Return
−0.94%
YTD Return
+2.38%
SummaryUpdated Jun 1, 2026
Pacira BioSciences, Inc. (NASDAQ:PCRX) is a Tampa, Florida-based specialty pharmaceutical company founded in 2006 that focuses on developing and commercializing non-opioid pain management and regenerative health solutions. Originally incorporated as Pacira Pharmaceuticals, the company rebranded to Pacira BioSciences in April 2019 to reflect its expanded focus beyond traditional pharmaceuticals into innovative biotechnology solutions. The company went public in February 2011 and has established itself as a leader in the non-opioid pain management space, addressing the critical need for alternatives to opioid-based treatments in surgical and chronic pain settings.
Similar companies
Latest newsMore news →
Pacira BioSciences reported second quarter 2026 total revenue of $192.4 million, a 6 percent year-over-year increase, and highlighted continued execution of its 5x30 strategy with solid revenue growth, durable cashflows, advancing pipeline, and commercial partnerships.31d agoUnitedHealthcare now provides separate reimbursement for Pacira BioSciences' EXPAREL across outpatient settings.65d agoPacira BioSciences agreed to divest its Pacira CryoTech subsidiary and related cryoanalgesia device assets to Zimmer, Inc. for up to $140 million.67d ago